All News

Delandistrogene moxeparvovec-rokl (Elevidys; Sarepta Therapeutics) is currently approved to treat Duchenne muscular dystrophy in 4- and 5-year-old patients who have a confirmed DMD gene mutation.

"It’s time for our industry to recognize the consequences of the lack of investment in maternal health and come together to bring forward innovations," Charlotte Owens, MD, stated.

The FDA announced it is allowing Florida to import medications in bulk from Canada at far lower prices than those offered in the United States; health insurance companies are revamping their technology to encourage more people to get their medications through the mail; nearly 17,000 patients with COVID-19 may have died after taking hydroxychloroquine during the first pandemic wave.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A qualitative interview study gauged patients’ experiences with belantamab mafodotin, which is used to treat relapsed/refractory multiple myeloma (RRMM) following failure on at least 4 prior therapies.

Patients with pulmonary arterial hypertension (PAH) had similar efficacy and safety profile when taking either oral Treprostinil or selexipag, indicating that Treprostinil would be an adequate replacement.

A topical therapy, PF-07038124 0.01%, administered once daily was more effective than the vehicle control in patients with atopic dermatitis (AD) and plaque psoriasis, a study finds.

A response to a previous article argued that using private capital to address health inequities in the United States only increased costs for payers without addressing health inequities.

The average direct cost for hospital treatment for patients with COVID-19 in the United States rose by 26% from 2020 to 2022; scientists have developed a new type of antibiotic to treat a deadly bacteria resistant to most current antibiotics; a survey conducted for Utah state officials gave some clues as to why millions of Americans lost Medicaid coverage last year.

Outcomes between 2 patients groups affected by uncontrolled type 2 diabetes and food insecurity were compared for change in hemoglobin A1C after 1 year of participation.

Asthma and allergy drugs such as montelukast and cetirizine were among a list of drugs frequently implicated in major drug-drug interactions.

Tumor grading via least differentiation analysis was found to be a way to measure the risk of lymph node metastasis (LNM) in patients with submucosal invasive colorectal cancer (CRC).

A population-based study drew a possible connection between gastrointestinal (GI) symptoms and the multiple sclerosis (MS) prodrome.

Gaps exist between self-reported and claims-based estimates of postpartum care among individuals who were covered by Medicaid for their delivery care, according to one study.

Drugmakers are expected to increase prices on more than 500 drugs early this month; the FDA approved nearly 50% more novel drugs in 2023 than in 2022; the number of Americans who were not pregnant and wanted abortion pills increased by nearly 10 times after the Supreme Court’s 2022 Roe v Wade decision leaked.

The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.

Patients who had cataracts, age-related macular degeneration, and/or glaucoma were at an increased risk of falling and sustaining fractures.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, recommends new novel topical therapies over topical steroids for patients with atopic dermatitis (AD).

A multidisciplinary team has proposed respiratory care guidance for pediatric and adult patients living with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK), with these recommendations meant to optimize DMD care day to day and in acute episodes.

Lawmakers contemplate the return of mental health institutions in response to the drug crisis; new measures to rein in insulin prices take effect; FDA intensifies efforts to curb the teen vaping epidemic.

The 2023 Fall Clinical Dermatology conference featured research on treatments for alopecia areata, acne, psoriasis, atopic dermatitis, and vitiligo.

While the first ustekinumab biosimilar, Wezlana, was approved in October 2023, a settlement with Johnson & Johnson (J&J) will keep it off the market until 2025, preventing competition, and causing purchasers to pay substantially more for the agent.

The most popular content from our Asembia coverage largely covered biosimilars.

A retrospective study found that instances of recurrent pulmonary hypertension due to vascular reocclusion or restenosis were extremely uncommon after balloon pulmonary angioplasty.

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with controls.

This qualitative study conducted interviews with caregivers of patients with spinal muscular atrophy (SMA) to explore their unique experiences and challenges in navigating health systems to access disease-modifying therapies.

This year’s top content from the annual San Antonino Breast Cancer Symposium (SABCS) is concentrated in 3 areas: health equity, benign breast disease, and fertility preservation following diagnosis.

The most popular reimbursement content of 2023 included coverage of the shift from the Oncology Care Model to the Enhancing Oncology Model, reactions to the 2024 Medicare Physician Fee Schedule, and concerns around denial of services in Medicare Advantage plans.

The study authors note that the Best Asthma Control Test for School Children and Adolescents (Best ACT-S) complements a previously developed questionnaire that assesses preschool-aged patients with asthma.

The topics included clinical staging of colorectal cancer, FDA approvals, and a study published in the print version of the American Journal of Managed Care®.